Drs. Adi Cohen and Elizabeth Shane are conducting a two-year treatment study for premenopausal women with idiopathic (unexplained) osteoporosis. This study will evaluate the efficacy of treatment with one year of romosozumab followed by one year of denosumab in premenopausal women with idiopathic osteoporosis. This an open-label study and not a randomized trial; all participants will receive both active treatments.

Dr. Adi Cohen is conducting a research study for women with pregnancy and lactation associated osteoporosis (PLO). This study aims to define the bone defect that leads to PLO and to better understand the causes, risk factors, predictors of disease severity, and natural history of PLO so that we can develop targeted treatment approaches. This study has been approved by the Columbia University Irving Medical Center IRB: #AAAR0960.

The National Osteoporosis Foundation (NOF) contracted with the independent actuarial firm Milliman to analyze the state-by-state economic and clinical impact of osteoporotic fractures suffered by Americans insured by Medicare. These reports provide the latest and most detailed state-level review of the incidence of osteoporotic fractures, their health care impact and associated Medicare costs. They are available for advocacy use to raise awareness and encourage policy makers to take action to improve bone health.